ADAM12 promotes temozolomide resistance in glioblastoma by activating the TNF-α - NF-κB pathway
Cancer Letters · 2025-06 · 620 · 217684
DOI: 10.1016/j.canlet.2025.217684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-06. Verfasst von Chunchao Cheng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Department of Neurosurgery, Tianjin Medical University General Hospital and Key Laborat…. Hauptthemen laut MEDLINE: Temozolomide, Drug Resistance, Neoplasm, NF-kappa B, Glioblastoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Special Project for Research and Development in Key areas of Guangdong Province, Ministry of Science and Technology of the People's Republic of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Development of temozolomide (TMZ) resistance is a critical factor contributing to a poor prognosis in glioma patients. TMZ resistance is also closely associated with the phosphorylation level of NF-κB, yet targeted inhibition of NF-κB activity in glioma can be leveraged to overcome TMZ resistance. ADAM12, a protein significantly overexpressed in glioma cells, is implicated in the pathogenesis and progression of glioma, yet its role in the development of TMZ resistance is completely understood. We found that knockdown of ADAM12 was shown to arrest the glioma cell cycle, enhance apoptosis, inhibit DNA damage repair mechanisms, and sensitize glioma cells to TMZ. Targeting ADAM12 in vivo was found to increase the sensitivity of glioma cells to TMZ. Survival analysis indicated that ADAM12 serves as a prognostic marker for TMZ treatment. Using ELISA and protein interaction predictions via docking simulation, we identified the TNF-α shedding function of ADAM12 as a critical regulator of glioma progression. Furthermore, in glioma cell lines with unmethylated MGMT, the knockdown of ADAM12 enhanced sensitivity to TMZ by inhibiting the TNF-α/NF-κB pathway and reducing MGMT expression. In all, these results demonstrated that ADAM12 aids in shedding of membrane-bound TNF-a to drive TMZ resistance in glioma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Department of Neurosurgery, Tianjin Medical University General Hospital and Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education…
- Neuro-Oncology Center, Tianjin Huanhu Hospital, Tianjin, 300350, China. Electronic address: liuxiaomintj@126.com.
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. Electronic address: Liangzeng@tjh.tjmu.edu.cn.
Förderung
- Special Project for Research and Development in Key areas of Guangdong Province
- Ministry of Science and Technology of the People's Republic of China
- China Postdoctoral Science Foundation
- National Key Research and Development Program of China
- Tianjin Municipal Health Commission
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin Municipality
Zitieren
APA
Cheng, C., Cui, L., Cui, X., Zhan, Q., Ju, J., Hong, B., Huang, Y., Ding, Y., Xu, H., Qiu, T., Kang, C., Liu, X., Wang, Q., & Zeng, L. (2025). ADAM12 promotes temozolomide resistance in glioblastoma by activating the TNF-α - NF-κB pathway. Cancer Letters, 620, 217684. https://doi.org/10.1016/j.canlet.2025.217684
Vancouver
Cheng C, Cui L, Cui X, Zhan Q, Ju J, Hong B, et al. ADAM12 promotes temozolomide resistance in glioblastoma by activating the TNF-α - NF-κB pathway. Cancer Letters. 2025;620:217684. doi:10.1016/j.canlet.2025.217684
BibTeX
@article{Cheng2025,
author = {Cheng, Chunchao and Cui, Longtao and Cui, Xiaoteng and Zhan, Qi and Ju, Jiasheng and Hong, Biao and Huang, Yanping and Ding, Yaqing and Xu, Hanyi and Qiu, Tian and Kang, Chunsheng and Liu, Xiaomin and Wang, Qixue and Zeng, Liang},
title = {ADAM12 promotes temozolomide resistance in glioblastoma by activating the TNF-α - NF-κB pathway},
journal = {Cancer Letters},
year = {2025},
volume = {620},
pages = {217684},
doi = {10.1016/j.canlet.2025.217684}
}
EUVIMED